


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended): A compound according to formula (I):



wherein:

R is selected from the group consisting of:

C<sub>2-6</sub> alkyl (optionally substituted by alkoxy, halogen, or C<sub>1-3</sub> alkylsulfanyl); C<sub>2-6</sub> alkenyl (optionally substituted by alkoxy, halogen, or C<sub>1-3</sub> alkylsulfanyl); C<sub>2-6</sub> alkynyl (optionally substituted by alkoxy, halogen, or C<sub>1-3</sub> alkylsulfanyl); (CH<sub>2</sub>)<sub>n</sub>—C<sub>3-6</sub> carbocycle (optionally substituted by alkoxy, halogen, or C<sub>1-3</sub> alkylsulfanyl); and (CH<sub>2</sub>)<sub>n</sub>—R<sub>4</sub>, wherein R<sub>4</sub> is selected from the group consisting of phenyl, furan, benzofuran, thiophene, benzothiophene, tetrahydrofuran, tetrahydropyran, dioxane, 1,4-benzodioxane [[or]] and benzo[1,3]dioxole; R<sub>4</sub> is optionally substituted by one or more substituents selected from Cl, Br, I, C<sub>1-3</sub> alkyl (optionally substituted by one to three F) and C<sub>1-2</sub> alkoxy (optionally substituted by one to three F);

R<sub>1</sub> represents hydrogen or C<sub>1-4</sub> alkyl;

R<sub>2</sub> represents C<sub>1-6</sub> alkyl, ArC<sub>1-4</sub> alkyl, wherein substitution is through the alkyl carbon, or Ar;

Ar is selected from the group consisting of phenyl, naphthyl, furyl, pyridyl, thienyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, benzofuranyl, indolyl, thiazolidinyl, isoxazolyl, oxadiazolyl, thiadiazolyl, morpholinyl, piperidinyl, piperazinyl, pyrrolyl, and pyrimidyl; all of which may be unsubstituted or substituted by one or more Z<sub>1</sub> or Z<sub>2</sub> groups;

Z<sub>1</sub> and Z<sub>2</sub> are, independently, selected from the group consisting of hydrogen, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sub>1</sub>, C(O)NRR<sub>1</sub>, CN, (CH<sub>2</sub>)<sub>n</sub>OH, NO<sub>2</sub>, halogen, NHR<sub>2</sub>, and NHC(O)R<sub>2</sub>; and  
n is an integer from 0 to 4; or a pharmaceutically acceptable salt thereof.

2. (Previously presented): A compound according to claim 1 selected from the group consisting of:

N-{2-[(Formylhydroxyamino)methyl]heptanoyl} benzenesulfonamide;

4-Chloro-N-{2-[(formylhydroxyamino)methyl]heptanoyl}  
benzenesulfonamide;

4-tert-Butyl-N-{2-[(formylhydroxyamino)methyl]heptanoyl}  
benzenesulfonamide;

N-{2-[(Formylhydroxyamino)methyl]heptanoyl} methanesulfonamide;

Butane-1-sulfonic acid

{2[(formylhydroxyamino)methyl]heptanoyl} amide;

Propane-2-sulfonic acid {2-[(formylhydroxyamino)methyl]-heptanoyl}  
amide;

4-{2-[(Formylhydroxyamino)methyl]heptanoylsulfamoyl} benzoic acid  
methyl ester;

4-Chloro-N-{2-[(formylhydroxyamino)methyl]-3-phenyl-propanoyl}  
benzenesulfonamide;

N-{2-[(Formylhydroxyamino)methyl]-3-phenyl-propanoyl}  
benzenesulfonamide;

5-Methyl-pyridine-2-sulfonic acid {2-[(formylhydroxyamino)methyl]  
heptanoyl} amide;

N-{2-[(Formylhydroxyamino)methyl]-4-phenyl-butanoyl}  
benzenesulfonamide;

Butane-1-sulfonic acid {2-[(formylhydroxyamino)methyl]-4-phenyl-  
butanoyl} amide;

Propane-2-sulfonic acid {2-[(formylhydroxyamino)methyl]-3-phenyl-  
propanoyl} amide;

Biphenyl-4-sulfonic acid {2-[(formyl-hydroxy-amino)-methyl]-heptanoyl}-amide;

5-Dimethylamino-naphthalene-1-sulfonic acid {2-[(formylhydroxyamino)methyl] heptanoyl} amide;

4-{2-[(Formylhydroxyamino)methyl]heptanoylsulfamoyl} benzoic acid propyl ester;

Naphthalene-1-sulfonic acid {2-[(formylhydroxyamino)methyl] heptanoyl} amide;

N-{2-[(Formylhydroxyamino)methyl]-5-methylhexanoyl} benzenesulfonamide;

5-Methyl-pyridine-2-sulfonic acid {2-[(formylhydroxyamino)methyl]-5-methyl-hexanoyl} amide;

4-Dimethylamino-N-{2-[(formylhydroxyamino)methyl]-5-methyl-hexanoyl} benzenesulfonamide;

N-[2-(2,6-Dichloro-benzyl)-3-(formylhydroxyamino)propanoyl] benzenesulfonamide;

Dimethylamino-N-{2-[(formylhydroxyamino)methyl]heptanoyl} benzenesulfonamide;

5-Methyl-pyridine-2-sulfonic acid [2-(2,6-dichlorobenzyl)-3-(formylhydroxyamino) propanoyl]amide;

5-Dimethylamino-naphthalene-1-sulfonic acid [2-(2,6-dichlorobenzyl)-3-(formylhydroxyamino)propanoyl]amide;

N-{2-[(Formylhydroxyamino)methyl]heptanoyl}-4-methyl-benzenesulfonamide;

N-{2-[(Formylhydroxyamino)methyl]heptanoyl}-4-phenoxy-benzenesulfonamide;

N-{2-[(Formylhydroxyamino)methyl]heptanoyl}-4-methoxy-benzenesulfonamide;

5-Methyl-pyridine-2-sulfonic acid {3-(3,4-dichlorophenyl)-2-[(formylhydroxyamino) methyl]propanoyl} amide;

N-{2-[(Formylhydroxyamino)methyl]hexanoyl} benzenesulfonamide;

5-Dimethylamino-naphthalene-1-sulfonic acid {2-[(formylhydroxyamino) methyl] hexanoyl} amide;  
N-{2-[(Formylhydroxyamino)methyl]hexanoyl}-4-phenoxy-  
benzenesulfonamide;  
5-Dimethylamino-naphthalene-1-sulfonic acid {2-[(formylhydroxyamino) methyl]-3-methyl-butanoyl} amide;  
5-Dimethylamino-naphthalene-1-sulfonic acid {(R)-2-  
[(formylhydroxyamino)methyl] heptanoyl} amide;  
5-Dimethylamino-naphthalene-1-sulfonic acid {2-[(formylhydroxyamino) methyl]pentanoyl} amide;  
Biphenyl-4-sulfonic acid {2-[(formylhydroxyamino)methyl]pentanoyl}  
amide;  
Biphenyl-4-sulfonic acid {2-[(formylhydroxyamino)-methyl]-4-methyl-  
pentanoyl} amide; and  
5-Dimethylamino-naphthalene-1-sulfonic acid {2-[(formylhydroxyamino) methyl]-4-methyl-pentanoyl} amide; or a pharmaceutically acceptable salt thereof.

3. (Currently amended): A method of treating a bacterial infection by administering to a subject in need of treatment a compound according to claim 1[;] or a pharmaceutically acceptable salt thereof.

4. (Currently amended): A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.